Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Jean‐Jacques Grob et al.|The Lancet|2012Cited by 3k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Uwe Trefzer et al.|The Lancet Oncology|2012Cited by 906
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell CarcinomaVicki Goodman, Richard Pazdur, Brian Booth et al.|Clinical Cancer Research|2007Cited by 495